Rectal Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Rectal Cancer - Pipeline Review, H2 2016

Rectal Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Rectal Cancer - Pipeline Review, H2 2016
Published Aug 17, 2016
107 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Rectal Cancer - Pipeline Review, H2 2016, provides an overview of the Rectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
- The report reviews pipeline therapeutics for Rectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rectal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Rectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rectal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in

  
Source:
Document ID
GMDHC8371IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Rectal Cancer Overview61
Therapeutics Development71
  Pipeline Products for Rectal Cancer Overview71
Rectal Cancer Therapeutics under Development by Companies81
Rectal Cancer Pipeline Products Glance92
  Clinical Stage Products91
  Early Stage Products101
Rectal Cancer Products under Development by Companies111
Rectal Cancer Companies Involved in Therapeutics Development127
  AbbVie Inc121
  Advaxis, Inc.131
  Cerulean Pharma, Inc.141
  Hanwha Chemical Corporation151
  Karyopharm Therapeutics, Inc.161
  Regeneron Pharmaceuticals Inc171
  Taiwan Liposome Company, Ltd.181
Rectal Cancer Therapeutics Assessment199
  Assessment by Monotherapy Products191
  Assessment by Target202
  Assessment by Mechanism of Action222
  Assessment by Route of Administration242
  Assessment by Molecule Type262
Drug Profiles2876
  axalimogene filolisbac Drug Profile2816
  CRLX-101 Drug Profile4411
  ganetespib Drug Profile5514
  HD-204 Drug Profile691
  nimotuzumab Drug Profile704
  selinexor Drug Profile7417
  TLC-388 Drug Profile912
  veliparib Drug Profile937
  ziv-aflibercept Drug Profile1004
Rectal Cancer Dormant Projects1041
Rectal Cancer Product Development Milestones1051
  Featured News &Press Releases1051
    Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting1051
    Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy1051
Appendix1062
  Methodology1061
  Coverage1061
  Secondary Research1061
  Primary Research1061
  Expert Panel Validation1061
  Contact Us1061
  Disclaimer1071

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Rectal Cancer - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rectal-Cancer-Pipeline-Review-H2-2016-2088-16397>
  
APA:
Global Markets Direct - Market Research. (2016). Rectal Cancer - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rectal-Cancer-Pipeline-Review-H2-2016-2088-16397>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.